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constituents through August 1, 2007, of which evidence from 27
were extracted using our criteria. Stakeholder comments on the
HTA process and decision methodology were distilled into 12
categories, ranging from impact of severity/rarity of disease on
acceptability of cost-effectiveness thresholds to over-reliance of
QALYs in decision-making. Compared to attributes reported for
other countries, NICE’s criteria and methods for health eco-
nomic assessment and decision-making varied substantially, such
as that of the model perspective, e.g., payer versus societal.
CONCLUSION: We found that aspects of NICE technology
appraisals garner criticism common to many stakeholders. This
underscores the need to reconsider how current health economic
and decision methodology might be improved. Furthermore,
country-level heterogeneity in HTA processes and methods sug-
gests the need to determine why these variations arise, and
whether they reﬂect societal preferences or misunderstandings of
appropriate methods.
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HOW MANDATORY PRICE REDUCTION OF REIMBURSED
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OBJECTIVE: Political objectives may alter economic rationale in
health care decision-making. The Hungarian government had
promised to reduce the prices and copayment of pharmaceuti-
cals, therefore 15% price cut was mandated to all reimbursed
pharmaceuticals from April 2004. Three months later the regu-
lation was abrogated by the Constitution Court. As the govern-
ment did not want to communicate a price increase, the level of
copayment remained the same, while the reimbursement level
was increased. It took two years to increase the copayment back
to the original level by a 7.5% reimbursement reduction in
February 2005, and by a further 7.5% reduction from February
2005 to July 2006. Our objective was to measure the impact of
price cut on the public pharmaceutical budget. METHODS: An
estimated public pharmaceutical spending was calculated based
upon projections from the expenditure in previous periods.
Only pharmaceuticals with reimbursement in April 2004 were
included into the analysis. The estimated expenditure was com-
pared to the real expenditure. Hungarian Forint was converted to
US$ by employing the quarterly exchange rate. RESULTS: In Q2
2004 the mandated price cut resulted in $39.65 million savings in
the pharmaceutical expenditure. In Q3-Q4 2004 the reduced
copayment generated $29.98 million increase in the drug budget.
Between Q1 2005 and Q2 2006 the impact of reduced copay-
ment was $42.42 million. CONCLUSION: The mandated price
cut and its subsequent abrogation resulted in $32.75 million
increase in the Hungarian public pharmaceutical expediture
between April 2004 and June 2006, as the government did not
dare to withdraw its promise on cheaper pharmaceuticals. Our
estimate is conservative, as the mandated price cut inﬂuenced
spending not only on pharmaceuticals with reimbursement in
April 2004, but via reference pricing also the spending on new




EFFECT OF PRESCRIPTION DRUG COVERAGE ON HEALTH
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OBJECTIVE: To estimate the effect of prescription drug insur-
ance on health, as measured by self-reported poor health status,
functional disability, and hospitalization among elderly with at
least three chronic conditions. METHODS: Analyses are based
on a nationally representative sample of non-institutionalized
elderly (>64 years of age) from the Medicare Current Beneﬁ-
ciary Survey (MCBS) for years 1992–2000. Estimates are
obtained using multivariable regression models that control for
observed characteristics and unmeasured person-speciﬁc effects
(i.e., ﬁxed effects). Fixed effects analysis uses within person
variation in drug coverage to estimate the effect of gaining or
losing coverage on outcome of interest (i.e., health). RESULTS:
In general, prescription drug insurance was not associated with
signiﬁcant changes in self-reported health, and hospitalization.
However, prescription drug coverage decreased functional dis-
ability slightly (4% improvement), although this was not sta-
tistically signiﬁcant. CONCLUSION: Findings suggest that
prescription drug coverage may have some health beneﬁts for
chronically ill.
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OBJECTIVE: During the 16 months preceding the start of the
Medicare prescription drug program (Part D), 22,359 vulnerable
Medicare beneﬁciaries with rheumatoid arthritis (RA) or mul-
tiple sclerosis (MS) participated in the Medicare Replacement
Drug Demonstration (MRDD), which provided access to spe-
cialty biologic medications. We examine beneﬁciary characteris-
tics associated with Part D enrollment among this population in
early 2006. METHODS: Predictors in multivariate logistic
regressions included female gender, age, race (white, black, or
other), region of the U.S., urban residence, Hierarchical Condi-
tion Category score (HCC; a measure of comorbidity), use of the
MRDD beneﬁt, subsidy level under the MRDD, self-report of
other drug coverage during the MRDD, and death within six
months of the start of Part D. RESULTS: Among 14,963 MRDD
beneﬁciaries with RA, 12,174 (81%) enrolled in Part D plans
during the ﬁrst half of 2006. Ninety percent (6646) of the 7396
beneﬁciaries with MS enrolled in a Part D plan—about 50%
higher than the rate of enrollment in the general Medicare popu-
lation. Female gender (OR = 1.5, 1.3–1.6), MRDD beneﬁt use
(OR = 2.6, 2.4–2.8), higher HCC score (OR = 1.07, 1.03–1.10),
other drug coverage during the MRDD (OR = 1.6, 1.5–1.7),
were associated with Part D enrollment. There were regional
differences as well. Older age (OR = 0.9, 0.9–0.9) and death
within 6 months (OR = 0.3, 0.3–0.4) were associated with not
enrolling in Part D. Separate regressions for the RA and MS
populations produced similar results. CONCLUSION: With the
inception of Medicare Part D, most MRDD beneﬁciaries with
RA and MS enrolled in Part D plans. Beneﬁciaries who had used
their MRDD beneﬁt and had worse health status—those who
appear to need prescription drug coverage most—were more
likely to enroll. Disproportionately high enrollment suggests that
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the Medicare prescription drug program provided this vulnerable
population with an important new source of drug coverage.
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CLINICALLY SIGNIFICANT DRUG-DRUG INTERACTION
PROFILES INTHE ELDERLY—A CALIFORNIA QUALITY
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OBJECTIVE: Drug-drug interactions (DDI) have been well asso-
ciated with signiﬁcant medical, safety, and economic conse-
quences, particularly in older and chronically ill patients. This
study examined several aspects of medication safety by quanti-
fying and proﬁling the prevalence, population exposure, and
characteristics of clinically signiﬁcant DDIs among Medicare
Part D utilizing beneﬁciaries. Lumetra and six California Medi-
care Advantage prescription drug plans (MAPD) and stand-alone
prescription drug plans (PDP) will collaboratively utilize results
to design effective quality improvement initiatives to minimize
adverse clinical outcomes due to these DDI’s. METHODS: This
study assessed the prevalence and population exposure of DDIs
among Medicare and dual eligible (i.e., Medicare +Medi-caid
status) beneﬁciaries enrolled across six of California’s Part D
MAPD and PDPs. Retrospective, cross sectional pharmacy
claims data from January 1, 2006 through December 31, 2006
were analyzed to obtain the frequency of drug interactions that
are clinically signiﬁcant and well-documented in the medical and
pharmacy literature. RESULTS: The analysis included 368,607
utilizing beneﬁciaries. The overall prevalence rate of DDI was
5.9%. The number of clinically signiﬁcant DDI cases was 7962
per 100,000 beneﬁciaries. Stratiﬁed analyses indicated that males
and older beneﬁciaries appear to be at a higher risk of incurring
a clinically signiﬁcant DDI. Risk of a DDI also increased as the
number of unique medications and/or number of prescribing
physicians increased per enrollee. CONCLUSION: The preva-
lence and characteristics of clinically signiﬁcant DDIs among
California elderly and chronically ill patients were positively
associated with certain demographic factors and health care
resource utilization proﬁles. Stratifying high-risk individuals with
discrete or multiple DDI’s will enable Part D MAPDs and PDPs
to perform in-depth case management in targeted individuals.
Point-of-service edits and information obtained from retrospec-
tive drug claims review can be used in conjunction to customize
meaningful intervention strategies.
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OBJECTIVE: To measure the impact of improvements in access
to care on Medicare spending growth for diagnostic imaging (DI)
services. METHODS: We modeled Medicare DI spending growth
as a function of growth in: enrollment; per-service payment;
access to care (% using  1 service); volume (services/user); and
intensity (relative value units per service used). We then used
Medicare Standard Analytic File 5% sample data from 2002–
2005 to decompose DI spending growth into these factors by
modality: standard (x-ray and ultrasound); and advanced (com-
puted tomography (CT), magnetic resonance (MR) and nuclear).
RESULTS: Aggregate DI service spending grew at an annual rate
of 15.2% during 2002–2005, and varied substantially by modal-
ity (x-ray 10.2%, ultrasound 11.7%, CT 19.6%, MR 18.5%,
nuclear 15.0%). Enrollment growth accounted for less than 15%
of this increase (range: 7.2% (CT)—13.3% (x-ray)), while the
impact of payment increases was far greater and varied widely
(range: 7.6% (nuclear)—54.0% (x-ray)). The share of DI spend-
ing growth attributable to improvements in access to care was:
x-ray (6.5%); ultrasound (19.1%); CT (30.4%); MR (49.0%);
and nuclear (30.5%). The contribution of volume growth to
overall spending growth ranged from 10.5% for MR to 24.1%
for CT. Service intensity growth accounted for less than 10% of
spending growth for x-ray, CT and MR; 17.9% and 33.0% of
spending growth for ultrasound and nuclear were due to service
intensity growth, respectively. CONCLUSION: Improved access
to care explains approximately 30%–50% of the growth in
Medicare spending for advanced diagnostic imaging services.
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OBJECTIVE: In early 2006, 18,820 vulnerable Medicare beneﬁ-
ciaries with RA or MS participating in a biologic drug demon-
stration program (MRDD) transitioned into Medicare Part D
plans. We compared the types of biologic drug coverage offered
by Part D plans. METHODS: We examined Part D plans’ cost
structure (e.g. premium, deductible, cost sharing) for the spe-
cialty biologic drugs offered during the MRDD: adalimumab,
etanercept, anakinra (for RA), interferon beta 1a and 1b, glati-
ramer acetate, and HP acthar gel (for MS). For MRDD and Part
D plans, we compared beneﬁciaries’ average out-of-pocket costs
(OOPC). RESULTS: Beneﬁciaries enrolled in 1061 stand-alone
(SA) and 705 Medicare Advantage (MA) Part D plans. All SA
plans and all but one MA plan covered etanercept, interferon
beta 1b, and glatiramer acetate. The proportion covering the
other drugs varied between 38–92%. MA plans were more likely
to cover anakinra, interferon beta 1a, and HP acthar gel than SA
plans (p < 0.05). All plans used co-insurance as the preferred
form of cost sharing; average co-insurance ranged from 25–31%
of the drug price. The majority of plans assumed >75% of the
cost sharing for each drug dispensing during the initial coverage
period, but only 2% of plans offered coverage during the cover-
age gap. On average, beneﬁciaries’ OOPC were greater under
Part D than the standard beneﬁt-structured MRDD. Patients
with a MRDD subsidy were signiﬁcantly less likely to receive a
Part D subsidy (p < 0.0001), because assets were considered in
addition to income in the granting of subsidies under Part D.
CONCLUSION: Many Part D plans assume some costs for
specialty biologic drugs to treat RA and MS. Beneﬁciaries still
ﬁnd themselves facing high OOPC due to drug price, plans’
preference for co-insurance, and scant coverage during the
coverage gap.
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OBJECTIVE: When private payers implement changes to control
health beneﬁt costs, the longer term consequences may not be
considered. The aim was to identify scientiﬁc studies that exam-
Abstracts A35
